Chinese Biopharma in C$290-million Deal for Unit of Canada's Therapure

3SBio Inc., a major Chinese biopharmaceutical with a focus on oncology, autoimmune diseases, and nephrology, has agreed to buy the contract development and manufacturing unit of Mississauga-headquartered Thereapure Biopharma for C$290 million, as part of a push by the Chinese biotech company into the North American market.

Use 'AND' or 'OR' to refine your search.

Use quotes " " to get exact matches or remove them to get more results.